The developers revealed the preliminary results on Monday, following trials conducted in the UK and Brazil.
Depending on the dosage, the vaccine showed varying efficiency of up to 90 percent, while the Pfizer vaccine is 95 percent effective and Russia’s Sputnik V is 92 percent effective.
“One dosing regimen showed vaccine efficacy of 90 percent when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62 percent efficacy when given as two full doses at least one month apart,” the AstraZeneca developers said in a statement, adding, “analysis from both dosing regimens resulted in an average efficacy of 70 percent.”
AstraZeneca’s CEO Pascal Soriot said the vaccine’s “efficacy and safety” showed it will be highly effective against the coronavirus and it will have an “immediate impact” on the COVID-19 crisis.
The announcement was welcomed by UK Health Secretary Matt Hancock who said the preliminary trial results were “fantastic news.”
“These figures … shows that the vaccine in the right dosage can be up to 90 percent effective,” he told Sky News. “We’ve got 100 million doses on order and should all that go well, the bulk of the rollout will be in the new year.”
The pilot vaccination program is expected to begin next month, Hancock added, expressing hope that “sometime after Easter things will be able to start to get back to normal.”
AstraZeneca has become the fourth company to publicly announce efficacy of its coronavirus vaccine. Russia became the first country to register a vaccine against coronavirus, with its solution, dubbed Sputnik V, showing around 92 percent effectiveness during trials. Earlier this month, Pfizer and America’s Moderna published results of testing their vaccines, which showed some 95 percent efficacy.
All the vaccines available have been made using different tech – while Russia’s Sputnik V is based on a human adenoviral vector, Pfizer’s and Moderna’s drugs utilized new messenger RNA technology.
AstraZeneca’s vaccine is based on chimpanzee adenovirus, which proved to be the less trusted approach, a recent YouGov poll has shown.
While the approach taken by developers of Sputnik V, on the contrary, garnered some nine times higher levels of trust.